A Lawful Peptide Is Not a Proven One

Two questions that are routinely collapsed

Most of this index argues in one direction: a peptide with no lawful route usually also has a thin human record, and readers are shown the second fact to explain the first. That correlation is real and it is not a mechanism. Lawfulness under section 503A turns on a nomination and a category; evidence turns on trials. Nothing connects them.

The clearest way to show that is a molecule where the two answers diverge, and this index acquired one in 2026. Vasoactive intestinal peptide appears in Category 1 of the section 503A bulks list published May 14, 2026 — the category for substances under evaluation, where a licensed pharmacy may compound for an individual patient with a valid prescription while review continues ^[1].

It is also a substance with no approved product at all. Drugs@FDA holds no record of vasoactive intestinal peptide or of aviptadil as the active ingredient of any drug product; in the same run and the same query form, bremelanotide returned one application and liraglutide returned fourteen, and a deliberately invented ingredient name returned none ^[2]. A pharmacy may lawfully prepare a substance that has never been approved for anything.

What the randomized record shows

The largest test of the synthetic peptide was run by the National Institutes of Health. TESICO randomized 471 participants with COVID-19-associated hypoxemic respiratory failure to intravenous aviptadil or matched placebo across 28 sites in the United States, with 461 in the modified intention-to-treat population. On the primary day-90 ordinal outcome the odds ratio was 1.11, with a 95 percent confidence interval of 0.80 to 1.55 and p = 0.54. Mortality to day 90 was 38 percent on aviptadil and 36 percent on placebo, a hazard ratio of 1.04. The independent data and safety monitoring board recommended stopping the aviptadil trial for futility on May 25, 2022, and the authors concluded that aviptadil did not significantly improve clinical outcomes ^[4].

The earlier and smaller trial pointed the same way on its own terms. It randomized 196 patients two to one and its primary endpoint — alive and free from respiratory failure at day 60 — returned an odds ratio of 1.6 with a 95 percent confidence interval of 0.86 to 3.11, which did not reach statistical significance; the authors state plainly that on the primary endpoint there was no difference between aviptadil and placebo, while reporting a secondary survival result at day 60 with an odds ratio of 2.0 and p = 0.035 ^[3].

The one thing controlled infusion of this peptide does reliably in people is not therapeutic. In a randomized, double-blind, placebo-controlled crossover study, a two-hour infusion provoked migraine attacks in 15 of 21 patients against 1 of 21 on placebo, p < .001 ^[5]. An early controlled study did find bronchodilation and protection against histamine-induced bronchoconstriction in asthmatic subjects ^[6], which remains the clearest positive controlled finding in the file and is forty-three years old.

Reading the two facts together

Neither fact corrects the other. The compounding status is accurate: a pharmacy may lawfully prepare this substance today, and a reader told otherwise has been misinformed. The evidence position is also accurate: the largest randomized trial of the synthetic peptide was stopped for futility, and no randomized evidence supports the indications the compounded preparation is marketed for.

What follows is a narrower claim than either side of the market usually makes. A lawful status tells a patient that a licensed pharmacy may prepare the substance under a prescription, that a prescriber is accountable for the decision, and that the preparation sits inside pharmacy regulation rather than outside it. Those are real protections and they are the ones the research-only material lacks entirely. None of them is a statement that the compound works.

The inverse error is just as common in the other direction. ARA-290 has five completed trials that administer the peptide to patients and sits in Category 3 with no lawful route at all. Evidence did not buy it a listing, and a listing has not bought this molecule evidence.

What a reader should do with this

Check the two records separately, and check the date on each. A category on the FDA list moves: GHK-Cu left Category 1 in April 2026 when its nominators withdrew, and part of it was restored in May, all within one document ^[1]. A trial record moves too, more slowly and in one direction.

The compoundable page carries the other substances in this position, and the monograph carries this one's dated ledger beside its counted literature. This index verifies no seller for this molecule and names none; a lawful status is a necessary condition for a supply route and not a sufficient one.

Elsewhere in this index